Beyond Borders: Ernst & Young’s Global Biotechnology Report 2007 Article Highlights

Beyond Borders: Ernst & Young’s Global Biotechnology Report 2007 Article Highlights: "Although there was no 'mega deal' in 2006, the biotechnology industry broke revenue and investment records around the world. In the US, there was unprecedented deal activity. In Europe and Canada, we saw double-digit revenue growth. In the Asia-Pacific region, companies moved aggressively and with confidence, using deals and creative business models to reinvent themselves. 'Beyond Borders: Ernst & Young's Global Biotechnology Report 2007' is our latest look at the global industry and presents geographic reporting for the Americas, Europe, and Asia-Pacific. Articles cover emerging challenges and risks and include perspectives from global biotechnology and pharmaceuticals industry leaders. The following articles introduce each geographic focus. * Global Biotech: The End of the Innocence (pdf, 547kb) Thirty years ago biotechnology companies were often founded by idealistic scientists and run more on vision than corporate experience. Now Big Pharma takes inspiration from the nimbler research and development (R&D) operations of its biotech neighbors, and the demand for alternative fuels and higher yield agriculture, as well as increasing regulation, has brought the maturing biotech industry firmly into adulthood. * Approaching Profitability: The Americas Pers"